Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
作者信息
Ganti Arun, Liu Weijian, Luo Suhong, Sanfilippo Kristen M, Roop Ryan, Lynch Ryan, Riedell Peter, O'Brian Katiuscia, Colditz Graham A, Carson Kenneth R
机构信息
Saint Louis Veterans Affairs Medical Center, Research Service, Saint Louis, MO, USA; Washington University School of Medicine, Saint Louis, MO, USA.
出版信息
Br J Haematol. 2014 Dec;167(5):699-702. doi: 10.1111/bjh.13026. Epub 2014 Jul 15.
Abstract
摘要
相似文献
1
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Br J Haematol. 2014 Dec;167(5):699-702. doi: 10.1111/bjh.13026. Epub 2014 Jul 15.
2
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Haematologica. 2013 Nov;98(11):1732-8. doi: 10.3324/haematol.2013.085134. Epub 2013 Jun 28.
3
Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15.
4
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):297-305. doi: 10.1016/j.clml.2012.06.004.
5
Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.
Hematol Oncol. 2019 Aug;37(3):308-309. doi: 10.1002/hon.2612. Epub 2019 Apr 26.
6
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Br J Haematol. 2014 May;165(4):489-96. doi: 10.1111/bjh.12765. Epub 2014 Feb 7.
7
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.
8
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).
Blood Cancer J. 2017 Jun 23;7(6):e576. doi: 10.1038/bcj.2017.57.
9
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
10
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Blood. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25.
引用本文的文献
1
Influence of Geriatric Nutritional Risk Index on Occurrence of Adverse Events and Duration of Treatment in Patients With Lymphoma Receiving R-CHOP Therapy.
In Vivo. 2023 May-Jun;37(3):1297-1303. doi: 10.21873/invivo.13208.
2
Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review.
Curr Med Chem. 2023;30(9):1003-1028. doi: 10.2174/0929867329666220806140204.
3
Clinicopathological characteristics and treatment outcome in obese patients with diffuse large B-cell lymphoma.
Transl Cancer Res. 2020 Oct;9(10):6116-6127. doi: 10.21037/tcr-20-1362.
4
The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).
J Geriatr Oncol. 2018 May;9(3):228-234. doi: 10.1016/j.jgo.2017.11.007. Epub 2017 Dec 8.
5
Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type.
Oncotarget. 2017 Jan 17;8(3):4245-4256. doi: 10.18632/oncotarget.13988.
6
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
Am J Hematol. 2016 Oct;91(10):1002-7. doi: 10.1002/ajh.24465. Epub 2016 Jul 22.
7
Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data.
Thromb Res. 2015 Apr;135(4):616-20. doi: 10.1016/j.thromres.2015.01.012. Epub 2015 Jan 14.
本文引用的文献
1
Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.
J Clin Oncol. 2012 Sep 10;30(26):3217-22. doi: 10.1200/JCO.2011.39.2100. Epub 2012 May 29.
2
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol. 2012 May 1;30(13):1553-61. doi: 10.1200/JCO.2011.39.9436. Epub 2012 Apr 2.
3
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy.
Cancer Chemother Pharmacol. 2011 Aug;68(2):301-7. doi: 10.1007/s00280-010-1487-6. Epub 2010 Oct 20.
4
Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.
BMJ. 2009 Jun 29;338:b2393. doi: 10.1136/bmj.b2393.
5
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
Ann Hematol. 2008 Apr;87(4):277-83. doi: 10.1007/s00277-007-0399-y. Epub 2007 Oct 20.
6
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
J Clin Oncol. 2004 Nov 1;22(21):4302-11. doi: 10.1200/JCO.2004.03.213. Epub 2004 Sep 20.
7
Interpretation of observational studies.
Heart. 2004 Aug;90(8):956-60. doi: 10.1136/hrt.2003.017269.
8
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.
Eur J Heart Fail. 2002 Jun;4(3):235-42. doi: 10.1016/s1388-9842(01)00201-x.
9
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.
J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90. doi: 10.1016/0895-4356(93)90103-8.
Zotero 插件